



Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid

| | | | | |
|---|---|--|--------------------|------------------|
| Patient ID SA00361735 | Patient Name TESTINGRNV, REPORTS NORM | Birth Date 1952-08-30 | Gender F | Age 65 |
| Order Number SA00361735 | Client Order Number SA00361735 | Ordering Physician CLIENT,CLIENT | Report Notes | |
| Account Information C7028846 DLMP Rochester | | Collected 05 Sep 2017 08:30 | | |

CA 19-9, Peritoneal Fluid

CA 19-9, Peritoneal Fluid

1 **SDL**

10 U/mL

A peritoneal fluid CA19-9 concentration = or < 32 U/mL does not rule-out a malignant cause of the ascites or the presence of micro-metastasis. In a study of 137 patients presenting with ascites, malignancies known not to secrete CA19-9 in serum routinely had CA19-9 concentrations = or < 32 U/mL in the peritoneal fluid. In addition, 51% of patients with malignancies known to secrete CA19-9 in serum (pancreatic, breast, gastric, colon, bladder, cholangiocarcinoma, gynecological cancers, peritoneal carcinomatosis, and hepatocellular carcinoma) had a CA19-9 level = or < 32 U/mL. This result should be correlated with serum levels to determine if CA19-9 is elevated in serum. A small percentage of the population does not synthesize CA19-9, or synthesizes low concentrations of the CA19-9 carbohydrate antigen. A low value in these individuals may be uninformative. Tumor marker tests are not specific for malignancy. This test

result should be interpreted in the context of clinical presentation, imaging and cytology findings.

The testing method is an immunoenzymatic assay manufactured by Beckman Coulter Inc. and performed on the UniCel Dxl 800.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Site

SDL

Right

Received: 06 Sep 2017 11:03

Reported: 06 Sep 2017 11:07

Laboratory Notes

- 1** This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

| Code | Laboratory | Address |
|------|---|--|
| SDL | Mayo Clinic Laboratories - Rochester Superior Drive | 3050 Superior Drive NW, Rochester MN 55901 |